

Pursuant to the provisions of article 227 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("**Grifols**") hereby informs about the following

OTHER RELEVANT INFORMATION

Grifols informs that, after the authorization for issue of the consolidated annual accounts, on 25 February 2022, KPMG Auditores, S.L. carried out an internal review over Grifols' subsidiary, Biomat USA, and due to such internal review the audit firm considered the need to conduct a balance sheet reclassification related to the non-controlling interest of GIC (Sovereign Fund of Singapore) on Biomat USA and Biomat Newco.

As a result of the abovementioned, the Company's board members, today, have proceed to restate the consolidated annual accounts of the fiscal year 2021. Such restated annual accounts include the reclassification of the financial instrument signed from net equity to financial liability.

Due to such reclassification, the total equity has been reduced by approximately €830M. Notwithstanding the above, the figures for total assets and liabilities, as well as the profit for the year have not been affected by this reclassification.

The aim had always been to consider the signed financial instrument as equity. For this reason, at the date of the restatement of these consolidated financial statements, Grifols is analysing the necessary modifications in the terms and conditions of the agreement in order to classify such transaction as an equity instrument, as it has always been the will of the parties.

The restated consolidated financial statements have been filed today in electronic format with the *Comisión Nacional del Mercado de Valores*.

In Barcelona, on 28 April 2022

Nuria Martín Barnés
Secretary to the Board of Directors